News
科思
/
/
/
Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

  • Categories:Academic Paper
  • Author:
  • Origin:
  • Time of issue:2016-08-12 09:23
  • Views:

(Summary description) Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement.

Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks

(Summary description) Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement.

  • Categories:Academic Paper
  • Author:
  • Origin:
  • Time of issue:2016-08-12 09:23
  • Views:
Information

  Percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) is routine treatment for patients with acute coronary syndromes (ACS). However, permanent metallic caging of the vessel has several shortcomings, such as side branch jailing and impossibility of late lumen enlargement. Moreover, DES PCI is affected by vasomotion impairment. In ACS a high thrombus burden and vasospasm lead to a higher risk of acute and late acquired stent malapposition than in stable patients. This increases the risk of acute, late and very late stent thrombosis. In this challenging clinical setting, the implantation of bioresorbable vascular scaffolds (BVS) could represent an appealing therapeutic option. Temporary vessel scaffolding has proved to have several advantages over metallic stent delivery, such as framework reabsorption, late lumen enlargement, side branch patency, and recovery of physiological reactivity to vasoactive stimuli. In the thrombotic environment of ACS, BVS implantation has the benefit of capping the thrombus and the vulnerable plaque. Bioresorbable vascular scaffolds also seems to reduce the incidence of angina during follow-up. Acute coronary syndromes patients may therefore benefit more from temporary polymeric caging than from permanent stent platform implantation. The aim of this review is to update the available knowledge concerning the use of BVS in ACS patients, by analyzing the potential pitfalls in this challenging clinical setting and presenting tricks to overcome these limitations.

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment
2021 12-25

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment

This is the world's first 3D printed fully degradable peripheral stent implanted in the human body, marking that my country's 3D printing fully degradable peripheral stent with completely independent intellectual property rights has taken the lead in entering the clinical trial stage, and it also marks that my country's 3D printing technology has advanced to the world's leading level. A big step.
Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises
2021 12-03

Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises

On December 1, the Beijing Economic and Information Bureau announced the list of the second to seventh batch of "specialized, special and new" small and medium-sized enterprises in Beijing in 2021. The list includes 1,150 small and medium-sized enterprises including Labtech, Digital Video, Geling Shentong, Moji Fengyun Technology, etc.
Beijing Amet was recognized as a "specialized, special and new" enterprise
2021 12-02

Beijing Amet was recognized as a "specialized, special and new" enterprise

On December 1, 2021, the Beijing Municipal Bureau of Economy and Information issued an announcement on the seventh batch of "specialized, refined, and new" small and medium-sized enterprises in 2021. The announcement announced that Beijing Amet Medical Equipment Co., Ltd. was recognized as a "specialized, refined and new" enterprise. This event marks that Amet, as an innovative enterprise, has reached a high level in terms of scientific research strength, technical level and influence, and has been recognized by the competent government departments.

Company Information

Beijing Advanced Medical Technologies,Ltd.Inc.

Contact Us

Address: Building 11, Zhongguancun Medical Equipment Park, No. 26, Yongwang West Road, Daxing District, Beijing

Tel:010-6297-7955           E-Mail:amt@ametcorp.com